Loading...
Products:Immunology >> Adaptive Immunity >> B Cells >> CD
If your product does not perform as described on this datasheet, we will refund or replace your product...
Read our guarantee »Anti-CD79a antibody
See all CD79a products (16) ...
Rabbit polyclonal to CD79a
IHC-P, ELISA, WBmore details
Reacts with
Human
Synthetic peptide (Human).
Human tonsil sections. Spleen.
Liquid
Shipped at 4°C. Upon delivery aliquot and store at -20°C or -80°C. Avoid repeated freeze / thaw cycles.
Preservative: 0.02% Sodium Azide
Constituents: PBS, pH 7.4
Concentration information loading...
Immunogen affinity purified
Polyclonal
IgG
Stem Cells >> Hematopoietic Progenitors >> Lymphoid >> B Lymphocytic Lineage
Cancer >> Tumor immunology >> CD markers
Immunology >> Immunoglobulins >> Receptors
Immunology >> Adaptive Immunity >> B Cells >> CD
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-CD79a antibody (ab5691)
(enlarge)
Our Abpromise guarantee covers the use of ab5691 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
IHC-P: 1/100. Perform heat mediated antigen retrieval before commencing with IHC staining protocol.
ELISA: Use a concentration of 0.1 - 1 µg/ml.
WB: Use a concentration of 0.5 - 2 µg/ml. Predicted molecular weight: 25 kDa.
Required in cooperation with CD79B for initiation of the signal transduction cascade activated by binding of antigen to the B-cell antigen receptor complex (BCR) which leads to internalization of the complex, trafficking to late endosomes and antigen presentation. Also required for BCR surface expression and for efficient differentiation of pro- and pre-B-cells. Stimulates SYK autophosphorylation and activation. Binds to BLNK, bringing BLNK into proximity with SYK and allowing SYK to phosphorylate BLNK. Also interacts with and increases activity of some Src-family tyrosine kinases. Represses BCR signaling during development of immature B cells.
B-cells.
Defects in CD79A are the cause of agammaglobulinemia type 3 (AGM3) [MIM:613501]. It is a primary immunodeficiency characterized by profoundly low or absent serum antibodies and low or absent circulating B cells due to an early block of B-cell development. Affected individuals develop severe infections in the first years of life. Note=Two different mutations, one at the splice donor site of intron 2 and the other at the splice acceptor site for exon 3, have been identified. Both mutations give rise to a truncated protein.
Contains 1 Ig-like C2-type (immunoglobulin-like) domain.
Contains 1 ITAM domain.
Phosphorylated on tyrosine, serine and threonine residues upon B-cell activation. Phosphorylation of tyrosine residues by Src-family kinases is an early and essential feature of the BCR signaling cascade. The phosphorylated tyrosines serve as docking sites for SH2-domain containing kinases, leading to their activation which in turn leads to phosphorylation of downstream targets. Phosphorylation of serine and threonine residues may prevent subsequent tyrosine phosphorylation.
Cell membrane. Following antigen binding, the BCR has been shown to translocate from detergent-soluble regions of the cell membrane to lipid rafts although signal transduction through the complex can also occur outside lipid rafts.
Target information above from: UniProt accessionP11912
The UniProt Consortium
The Universal Protein Resource (UniProt) in 2010
Nucleic Acids Res. 38:D142-D148 (2010).
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-CD79a antibody (ab5691)

Human tonsil stained with ab5691.
This product has been referenced in:
See 1 publication for this product
Publishing research using ab5691? Please let us know so that we can cite the reference in this datasheet
Concentration of lot no. is
Concentration not available for this lot.
Find concentration of your lot:
Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"
Call 01223 696 000 or contact us
